Highbridge Capital Management »

Revance Therapeutics shares owned by Highbridge Capital Management

Quarter-by-quarter ownership of Revance Therapeutics shares owned by Highbridge Capital Management from 13F filings

Historical chart of Highbridge Capital Management investment in Revance Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Revance Therapeutics held by Highbridge Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Revance Therapeutics by Highbridge Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $14B 20M 721.47
2023-09-30 $17M 21M 0.82

More positions owned by Highbridge Capital Management

Ishares Tr Option Put Option
Occidental Pete Corp Warrant (Principal) (OXY.WS)
Ford Mtr Co Del Bond (Principal)
Occidental Pete Corp Option Put Option
Liberty Broadband Corp Common (LBRDK)
Nice Bond (Principal)
Gamida Cell Bond (Principal)
Sarepta Therapeutics Bond (Principal)
Integra Lifesciences Hldgs C Bond (Principal)
Pdd Holdings Bond (Principal)
American Airlines Group Bond (Principal)
Lci Inds Bond (Principal)
Tilray Brands Bond (Principal)
Omnicell Bond (Principal)
Sea Bond (Principal)

View all positions for Highbridge Capital Management

Top funds holding Revance Therapeutics

Franklin Resources
D. E. Shaw & Co
Graham Capital Management
Context Capital Management
Aviva
Highbridge Capital Management
SSI Investment Management
Calamos Advisors
Amundi
Credit Suisse
CSS
Citigroup
First Hawaiian Bank
William Blair $ Company
Barclays

View all funds holding Revance Therapeutics